The best way to flatten the curve for coronavirus pandemic is mass testing.
Governments prefer coronavirus specific antibody, immunochromatography testing for mass screening, whether symptoms are observed or not, to determine who can go back to normal daily life.
Test volumes are on the rise, however even in the most diligent countries % of population tested remains less than 5%.
GNZ – COVID 19 is a rapid immunochromatography test for diagnosis of two scenarios:
whether a patient is currently infected by COVID-19 can be diagnosed from the first day of infection using swap samples from throat and nose and by detecting virus specific surface proteins and antigens
whether a patient has been infected in the past by COVID-19 can be determined using a blood sample and screening his/her body’s immune response to the infection, i.e. whether COVID-19 specific IgG, IgM antibodies have been developed.
Both tests give results in less than 15 minutes and do not require a laboratory facility.
GNZ – COVID 19 is currently at beta prototype stage. As of May 2020, GNZ – Covid 19 has been awarded a grant of 563k TL from Scientific and Technological Research Council of Turkey (TUBITAK)